Figure 3.

Expression of circRNA HECTD1 in recurrence patients and non‐recurrence patients. Recurrence patents had higher relative expression of circRNA HECTD1 than that in non‐recurrence patients (A). Expression of circRNA HECTD1 could differentiate recurrence patients and non‐recurrence patients (B). Comparison between recurrence patients and non‐recurrence patients was analyzed by Wilcoxon rank sum test. P < 0.05 was considered significant. ROC analysis was conducted to detect the ability of circRNA HECTD1 in differentiating recurrence patients from non‐recurrence patients. CircRNA HECTD1, circular RNA HECT domain E3 ubiquitin protein ligase 1; AUC, area under the curve; ROC, receiver operating characteristic